Evidence map›Paper›PMID 42768030›Full record

ArticleNature communications2026

PUM3 is an essential suppressor of replication stress in homologous recombination deficient breast cancer.

Valeria Amodeo, Daniel Weekes, Nicolae Balan, Rebeca Uceda Castro, Nadja D'Uonno, Asha Konde, Elodie Noel, Luisa Robbez-Masson, Jennifer Trendell, Maya Shlomi and 13 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Valeria Amodeo *The Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Daniel Weekes *The Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Nicolae BalanThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Rebeca Uceda CastroThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Nadja D'UonnoThe Breast Cancer Now Research Unit, King's College London, London, UK.ORCID http://orcid.org/0009-0008-5585-7083
Asha KondeThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Elodie NoelThe Breast Cancer Now Research Unit, King's College London, London, UK.
Luisa Robbez-MassonThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Jennifer TrendellThe Breast Cancer Now Research Unit, King's College London, London, UK.ORCID http://orcid.org/0000-0002-5517-0352
Maya ShlomiThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Callum WalkerThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Anjan VenkateshConway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
Colm J RyanConway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.ORCID http://orcid.org/0000-0003-2750-9854
Sarah C MoserDivision of Molecular Pathology, The Netherlands Cancer Institute, Oncode Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-1678-4079
Jos JonkersDivision of Molecular Pathology, The Netherlands Cancer Institute, Oncode Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-9264-9792
Laurence H PearlDivision of Structural Biology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-6910-1809
Antony W OliverGenome Damage and Stability Centre, University of Sussex, Brighton, UK.ORCID http://orcid.org/0000-0002-2912-8273
Dragomir B KrastevThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-4298-7272
Syed HaiderThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-6685-5480
Anita GrigoriadisThe Breast Cancer Now Research Unit, King's College London, London, UK.ORCID http://orcid.org/0000-0003-3434-201X
Stephen J PettittThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Stephen.Pettitt@icr.ac.uk.ORCID http://orcid.org/0000-0003-3313-3857
Christopher J LordThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Chris.Lord@icr.ac.uk.ORCID http://orcid.org/0000-0002-3226-0515
Andrew N J TuttThe Precision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Andrew.Tutt@icr.ac.uk.ORCID http://orcid.org/0000-0001-8715-2901

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most Triple Negative Breast Cancers (TNBCs) are p53 mutant high-grade invasive ductal carcinomas with a basal-like transcriptional programme. A large proportion of TNBCs also have mutation signatures indicating defective homologous recombination (HR) DNA repair. While HR deficiency is mutagenic and oncogenic, it can also compromise cell fitness. Here, we show that BLBCs harbouring the recurrent 9p21.3-9p24 amplicon, and particularly those that are HR-defective, overexpress PUM3 (Pumilio RNA binding family member 3). PUM3 inhibition is also synthetic lethal in tumour cells that overexpress PUM3 including those that have BRCA1/BRCA2 defects. Mechanistically, PUM3 suppresses transcription-mediated replicative stress and R-loop accumulation, thereby preventing DNA damage that would normally require RAD51-mediated repair. Transcription/replication collisions are commonly resolved by topoisomerase TOP1; without PUM3, TOP1 DNA chromatin localisation is impaired, revealing one mechanism by which PUM3 limits replication stress. PUM3 is therefore required for the continued fitness of a BLBC subset, allowing tolerance of HR deficiency's deleterious effects.

Indexed as

Breast NeoplasmsDNA ReplicationHomologous RecombinationRNA-Binding ProteinsBRCA1 ProteinBRCA2 ProteinCell Line, TumorDNA DamageDNA Topoisomerases, Type IGene Expression Regulation, NeoplasticHumansRad51 RecombinaseR-Loop StructuresBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanDNA Topoisomerases, Type IRad51 RecombinaseRNA-Binding Proteins

Identifiers

PMID42768030
PMCPMC13594191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.